PL1603584T3 - Aplidyna do leczenia szpiczaka mnogiego - Google Patents

Aplidyna do leczenia szpiczaka mnogiego

Info

Publication number
PL1603584T3
PL1603584T3 PL04720081T PL04720081T PL1603584T3 PL 1603584 T3 PL1603584 T3 PL 1603584T3 PL 04720081 T PL04720081 T PL 04720081T PL 04720081 T PL04720081 T PL 04720081T PL 1603584 T3 PL1603584 T3 PL 1603584T3
Authority
PL
Poland
Prior art keywords
aplidine
multiple myeloma
myeloma treatment
treatment
medicament
Prior art date
Application number
PL04720081T
Other languages
English (en)
Inventor
Joseph R Bertino
Daniel Medina
Glynn Thomas Faircloth
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Dana Farber Cancer Inst Inc
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Pharma Mar Sa filed Critical Dana Farber Cancer Inst Inc
Publication of PL1603584T3 publication Critical patent/PL1603584T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04720081T 2003-03-12 2004-03-12 Aplidyna do leczenia szpiczaka mnogiego PL1603584T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14
PCT/GB2004/001062 WO2004080477A1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment
EP04720081A EP1603584B1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment

Publications (1)

Publication Number Publication Date
PL1603584T3 true PL1603584T3 (pl) 2009-02-27

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04720081T PL1603584T3 (pl) 2003-03-12 2004-03-12 Aplidyna do leczenia szpiczaka mnogiego

Country Status (20)

Country Link
US (1) US7381703B2 (pl)
EP (1) EP1603584B1 (pl)
JP (1) JP4584245B2 (pl)
KR (1) KR101160320B1 (pl)
AT (1) ATE406171T1 (pl)
AU (1) AU2004218883B2 (pl)
CA (1) CA2519789C (pl)
CY (1) CY1108599T1 (pl)
DE (1) DE602004016126D1 (pl)
DK (1) DK1603584T3 (pl)
ES (1) ES2312979T3 (pl)
IL (1) IL170136A (pl)
MX (1) MXPA05009742A (pl)
NO (1) NO334264B1 (pl)
NZ (1) NZ541611A (pl)
PL (1) PL1603584T3 (pl)
PT (1) PT1603584E (pl)
RU (1) RU2335294C2 (pl)
SI (1) SI1603584T1 (pl)
WO (1) WO2004080477A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
UA83022C2 (uk) 2003-03-12 2008-06-10 Фарма Мар, С.А. Аплідин для комбінованої терапії лейкозу та лімфоми
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
RS54928B1 (sr) * 2006-02-28 2016-10-31 Pharma Mar Sa Poboljšano lečenje multiplog mijeloma
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2009002553A1 (en) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
US20110009335A1 (en) * 2008-03-07 2011-01-13 Pharma Mar, S.A. Anticancer Treatments
CN102065865B (zh) * 2008-05-16 2013-03-20 马尔药品公司 多发性骨髓瘤治疗
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
DE69431071T2 (de) * 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
CA2259443A1 (en) 1996-07-03 1998-01-15 Stephen Clive Loftus Container
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
JP4327260B2 (ja) * 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DE69923322T2 (de) * 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
HK1046846A1 (zh) 1999-05-25 2003-01-30 Point Therapeutics, Inc. 包含boroproline的抗肿瘤复合物
ATE363910T1 (de) * 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
EP1276491B9 (en) 2000-04-07 2007-02-28 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7175849B2 (en) * 2000-10-05 2007-02-13 Immunex Corporation Nectin polypeptides
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2003033013A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
UA83022C2 (uk) 2003-03-12 2008-06-10 Фарма Мар, С.А. Аплідин для комбінованої терапії лейкозу та лімфоми

Also Published As

Publication number Publication date
CY1108599T1 (el) 2014-04-09
WO2004080477A1 (en) 2004-09-23
KR20060006779A (ko) 2006-01-19
JP4584245B2 (ja) 2010-11-17
AU2004218883B2 (en) 2009-10-01
US20060172926A1 (en) 2006-08-03
CA2519789A1 (en) 2004-09-23
ATE406171T1 (de) 2008-09-15
US7381703B2 (en) 2008-06-03
IL170136A (en) 2014-04-30
PT1603584E (pt) 2008-11-21
EP1603584A1 (en) 2005-12-14
RU2005131578A (ru) 2006-01-27
KR101160320B1 (ko) 2012-06-26
JP2006519828A (ja) 2006-08-31
WO2004080477A8 (en) 2004-11-11
EP1603584B1 (en) 2008-08-27
NO334264B1 (no) 2014-01-20
DK1603584T3 (da) 2009-01-05
DE602004016126D1 (de) 2008-10-09
CA2519789C (en) 2012-07-03
SI1603584T1 (sl) 2009-02-28
RU2335294C2 (ru) 2008-10-10
MXPA05009742A (es) 2006-05-25
NO20054668L (no) 2005-10-11
NZ541611A (en) 2008-04-30
ES2312979T3 (es) 2009-03-01
US20070149445A9 (en) 2007-06-28
AU2004218883A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
MY146794A (en) Use of an alpha-2-delta ligand for the treatment of luts
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
GB0218879D0 (en) Medical treatment
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
WO2004080421A3 (en) Improved antitumoral treatments
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
GB0223854D0 (en) Therapeutic treatment
IL175579A0 (en) Epithelium treatment methods and devices for treating the epithelium
GB0210464D0 (en) Therapeutic treatment
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
GB0327493D0 (en) Treatment medicament
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
AU2003265321A8 (en) Treatments and methods for the treatment, diagnosis and prophylaxis
UA70017A (en) Method for conservative treatment of chronic tonsillitis in adults
AU2003209489A1 (en) Medical use of captopril for the treatment and prophylaxis of cancer
UA2826U (uk) Спосіб лікування розсіяного склерозу
UA49672A (uk) Спосіб допологової підготовки
UA32314A (uk) Спосіб лікування некротичного панкреатиту